Browsing Tag
tuspetinib
2 posts
Hanmi Pharmaceutical to acquire Aptose Biosciences in C$2.41-per-share deal with 28% premium
Find out how Hanmi Pharmaceutical’s acquisition of Aptose Biosciences is reshaping the AML treatment landscape today!
Aptose Biosciences begins TUSCANY trial with innovative AML triplet therapy
Aptose Biosciences Inc., a clinical-stage precision oncology company, has reached a significant milestone in its quest to transform…